All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

How are transplant options evolving for patients with ALL?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the ALL Hub spoke to Aaron Logan, UCSF, San Francisco, US. We asked, How are transplant options evolving for patients with acute lymphoblastic leukemia (ALL)?

How are transplant options evolving for patients with ALL?

Logan begins by highlighting that increased use of alternative donors, especially haploid donors, has allowed transplants for people who wouldn't have had one previously. He goes on to outline improvements in criteria to identify patients that would benefit from transplant e.g. MRD positivity or high risk genetic lesions. Finally, he discusses advances in bridging therapies such as lintuzumab and the evolution of CAR T-cell therapy.

 

Share: